A5014844902- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Pediatric health and respiratory diseases
- Sinusitis and nasal conditions
- Genomics, phytochemicals, and oxidative stress
- Nasal Surgery and Airway Studies
- Olfactory and Sensory Function Studies
- Respiratory and Cough-Related Research
- Dermatology and Skin Diseases
Beijing Tongren Hospital
2021-2025
Capital Medical University
2021-2025
Beijing Institute of Neurosurgery
2020-2025
Ministry of Education of the People's Republic of China
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2025
Seasonal allergic rhinitis (SAR) is a global health issue, and the current standard of care (SoC) has limited effectiveness in controlling disease. There need for innovative treatments to better manage uncontrolled SAR advance beyond uniform SoC, biologics targeting type 2 inflammation driving promising. To evaluate efficacy safety Stapokibart, humanized monoclonal antibody interleukin-4 receptor subunit alpha, as an add-on therapy patients with SAR. The PHECDA multicenter, randomized,...
Seasonal allergic rhinitis (SAR) places a significant socioeconomic burden, particularly on individuals with poorly managed recurrent and severe symptoms despite standard-of-care treatment. Stapokibart, humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha, inhibits its interaction both IL-4 IL-13 in type 2 inflammation. Here we aim to assess efficacy safety of stapokibart as an add-on therapy adults moderate-to-severe SAR. The study was phase 3...
Background: Allergic rhinitis (AR) is traditionally subdivided into seasonal AR (SAR) and perennial (PAR) according to the type of allergen occurrence symptoms during year. There are currently no reports on comparison trait profiles for SAR PAR exposure. Purpose: The purpose this study was analyze clinical characteristics respective exposure periods provide valuable information development treatment strategies. Methods: This performed between August 1, 2021, January 31, 2022, in Department...